ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
You have a diagnosis of non-small cell lung cancer.
You have received no prior chemotherapy.
You have at least one measurable lesion.
You have an adequate performance status.
You are at least 18 years of age.
You have previously received chemotherapy for your lung cancer.
You have received radiation within the last 30 days.
You have active infection or other serious condition.
You have brain metastasis.
You have recently lost a significant amount of weight.